So we see kind of optionality going forward for the longer term outlook of our life cycle management programs, while optimizing the current momentum we have now. Obviously, with the interest in IH and the completion of enrollment and looking forward to topline data in the fourth quarter, as well as interest in the Prader-Willi syndrome program from that patient community that we’ve been kind of working with over a number of years now and interest in advancing into Phase III at this point.
Jason Gerberry: Ask a quick follow up on that.
Dr. Jeffrey Dayno: Sure.
Jason Gerberry: With the thinking be to launch a next gen before going to market for PWS or IH, just thinking if you had the lots of reformulation against a generic version of your WAKIX, the track record on that could be a little bit more challenging versus like if you can get a reformulation out first, it would seem like that would have, maybe a more competitive pathway in the market?
Jeffrey Dierks: Yeah. I mean I think that, based on the new formulation programs we’re working on, that’s a potential scenario as well and I think that’s — we’re looking at that potential sort of in the near-term, along with the longer term outlook with some of the formulation work that we’re doing. So we will have more color on that as the new formulation programs progress later this year.
Jason Gerberry: Got it. Thanks.
Jeffrey Dierks: Yeah. Thanks, Jason.
Operator: Thank you. We’ll take our next question from Corinne Jenkins with Goldman Sachs.
Corinne Jenkins: Yeah. Good morning. A couple from me. Maybe first, can you talked about the new patient growth in the quarter, what portion of these patients are coming through via sleep specialist population versus the prescribing population you’ve described it, not being enrolled in the oxybate REMS program?
Dr. Jeffrey Dayno: Good morning, Corinne. Jeff in terms of the patients and where they’re coming from in terms of the prescriber base.
Jeffrey Dierks: Sure. Corinne, I mean, we’re seeing patients come through both those that are healthcare professionals enrolled in the oxybate REMS program, the sleep specialists. But we’re also seeing patients come through in the approximate 5,000 healthcare professionals that are not enrolled in the oxybate REMS program. I know there have been questions in the past looking at proportionality of what percentage of the patients reside more in the oxybate REMS enrolled doctors versus the non. And what you would say is that, the majority of the patients tend to be in the oxybate REMS enrolled healthcare professional audience. They tend to be more of sleep specialists. But there is meaningful percentage of our new patients that are coming from that, approximately 5,000 healthcare professionals outside the oxybate REMS program.
That’s what we’re seeing our new prescribers coming from, the depth of prescribing and the new patients are coming out of the other portion of the oxybate REMS enrolled doctors.
Corinne Jenkins: Okay. And then on the Phase III Prader-Willi study, what assumptions can you share that underpin the size of that study and the powering decisions that went into its design?
Dr. Jeffrey Dayno: Yeah. Go ahead, Kumar.
Dr. Kumar Budur: Good morning, Corinne. Thanks for the question. We had a positive meeting with the FDA and we aligned on this study design, and as we mentioned earlier, we plan to initiate this study in the fourth quarter of 2023. We plan to provide details on the study design at the time of study initiation.
Corinne Jenkins: Okay. Thank you.
Dr. Jeffrey Dayno: Thank you.
Operator: Thank you. And our last question will come from Charles Duncan with Cantor Fitzgerald.
